The Latest Breaking News from Pfizer

The FDA has granted Breakthrough Therapy Designation to Pfizer Inc's (NYSE:PFE) respiratory syncytial virus (RSV) vaccine candidate (PF-06928316 or RSVpreF) to prevent lower respiratory tract disease caused by RSV in 60 years of age or older. The positive results primarily inform the FDA decision of Phase 2a study evaluating the safety, immunogenicity, and efficacy…

BioNTech partner markets the advanced-tech inoculation in Hong Kong, Macao and Taiwan as regulators haven’t cleared the shots for the mainland

Moderna says it will ask regulators to authorize its COVID-19 vaccine for children under 6 but several hurdles need to be cleared before the shots could become available

Pfizer Inc (NYSE:PFE) has announced topline results from a Phase 3 study of etrasimod in moderately to severely active ulcerative colitis (UC).  In the study, etrasimod patients achieved statistically significant improvements in the primary endpoint of clinical remission at week 12 compared with placebo.  Statistically significant improvements were achieved in all key secondary…

Kids, prep those arms.

Rollout has begun across the UK for the Covid spring booster. Here's who is eligible for the second booster dose and when young people will be able to get their fourth coronavirus vaccine

Assertions by pharmaceutical company executives have created pressure for scientists and politicians to take action

Moderna says its COVID-19 vaccine works in babies, toddlers and preschoolers

Here's a roundup of top developments in the biotech space over the last 24 hours.

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

Vaccine-makers are seeking approval for a second booster. Some doctors don’t think the evidence is strong